Fuan Pharmaceutical (Group) Co., Ltd. (SHE:300194)
4.280
+0.120 (2.88%)
Jun 3, 2025, 2:45 PM CST
SHE:300194 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 2,391 | 2,571 | 2,378 | 2,388 | 2,343 | Upgrade
|
Other Revenue | - | 76.94 | 44.22 | 64.71 | 25.68 | Upgrade
|
Revenue | 2,391 | 2,648 | 2,422 | 2,453 | 2,368 | Upgrade
|
Revenue Growth (YoY) | -9.68% | 9.33% | -1.28% | 3.58% | -14.83% | Upgrade
|
Cost of Revenue | 1,125 | 1,281 | 1,066 | 935.97 | 839.22 | Upgrade
|
Gross Profit | 1,266 | 1,367 | 1,355 | 1,517 | 1,529 | Upgrade
|
Selling, General & Admin | 822.2 | 1,021 | 1,092 | 1,217 | 1,238 | Upgrade
|
Research & Development | 153.22 | 148.79 | 142.89 | 120.38 | 86.94 | Upgrade
|
Other Operating Expenses | -17.14 | 15.31 | 16.28 | 28.08 | 29.64 | Upgrade
|
Operating Expenses | 958.29 | 1,182 | 1,255 | 1,370 | 1,353 | Upgrade
|
Operating Income | 308.18 | 184.51 | 100.24 | 147.59 | 176.13 | Upgrade
|
Interest Expense | - | -29.57 | -26.94 | -20.45 | -10.16 | Upgrade
|
Interest & Investment Income | 76.99 | 109.41 | 90.07 | 74.46 | 53.65 | Upgrade
|
Currency Exchange Gain (Loss) | - | 0.66 | 1.47 | -0.59 | -1.74 | Upgrade
|
Other Non Operating Income (Expenses) | -5.5 | -0.85 | -1.4 | -1.76 | -0.61 | Upgrade
|
EBT Excluding Unusual Items | 379.67 | 264.17 | 163.44 | 199.26 | 217.27 | Upgrade
|
Impairment of Goodwill | - | -224.51 | -22.97 | -201.06 | - | Upgrade
|
Gain (Loss) on Sale of Investments | -32.74 | 0.41 | 0.42 | 0.75 | 3.25 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.01 | 220.65 | 4.85 | 0.31 | 1 | Upgrade
|
Asset Writedown | -34.74 | -3.55 | -2.44 | -626.17 | -2.69 | Upgrade
|
Other Unusual Items | - | 33.19 | 46.07 | 34.93 | 22.29 | Upgrade
|
Pretax Income | 312.2 | 290.36 | 189.35 | -591.99 | 241.12 | Upgrade
|
Income Tax Expense | 34.03 | 55.95 | -11.47 | 17.61 | 35.35 | Upgrade
|
Earnings From Continuing Operations | 278.17 | 234.41 | 200.82 | -609.59 | 205.77 | Upgrade
|
Minority Interest in Earnings | 1.67 | -2.54 | 3.79 | 312.68 | 3.6 | Upgrade
|
Net Income | 279.84 | 231.87 | 204.61 | -296.91 | 209.37 | Upgrade
|
Net Income to Common | 279.84 | 231.87 | 204.61 | -296.91 | 209.37 | Upgrade
|
Net Income Growth | 20.69% | 13.32% | - | - | -28.50% | Upgrade
|
Shares Outstanding (Basic) | 1,166 | 1,220 | 1,204 | 1,188 | 1,163 | Upgrade
|
Shares Outstanding (Diluted) | 1,166 | 1,220 | 1,204 | 1,188 | 1,163 | Upgrade
|
Shares Change (YoY) | -4.46% | 1.40% | 1.34% | 2.10% | -0.70% | Upgrade
|
EPS (Basic) | 0.24 | 0.19 | 0.17 | -0.25 | 0.18 | Upgrade
|
EPS (Diluted) | 0.24 | 0.19 | 0.17 | -0.25 | 0.18 | Upgrade
|
EPS Growth | 26.32% | 11.77% | - | - | -28.00% | Upgrade
|
Free Cash Flow | 61.8 | 113.3 | -43.6 | -155.91 | -181.98 | Upgrade
|
Free Cash Flow Per Share | 0.05 | 0.09 | -0.04 | -0.13 | -0.16 | Upgrade
|
Dividend Per Share | - | 0.050 | 0.050 | - | 0.050 | Upgrade
|
Gross Margin | 52.96% | 51.63% | 55.97% | 61.85% | 64.56% | Upgrade
|
Operating Margin | 12.89% | 6.97% | 4.14% | 6.02% | 7.44% | Upgrade
|
Profit Margin | 11.70% | 8.76% | 8.45% | -12.10% | 8.84% | Upgrade
|
Free Cash Flow Margin | 2.58% | 4.28% | -1.80% | -6.35% | -7.68% | Upgrade
|
EBITDA | 505.63 | 392.55 | 284.11 | 321.89 | 331.9 | Upgrade
|
EBITDA Margin | 21.14% | 14.83% | 11.73% | 13.12% | 14.01% | Upgrade
|
D&A For EBITDA | 197.45 | 208.04 | 183.87 | 174.29 | 155.78 | Upgrade
|
EBIT | 308.18 | 184.51 | 100.24 | 147.59 | 176.13 | Upgrade
|
EBIT Margin | 12.89% | 6.97% | 4.14% | 6.02% | 7.44% | Upgrade
|
Effective Tax Rate | 10.90% | 19.27% | - | - | 14.66% | Upgrade
|
Revenue as Reported | - | 2,648 | 2,422 | 2,453 | 2,368 | Upgrade
|
Advertising Expenses | - | 2.44 | 0.48 | 0.5 | 1.35 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.